Open access
Open access
Powered by Google Translator Translator

Neurology

Perspective: Nervous system consequences of COVID-19.

21 Jan, 2022 | 10:10h | UTC

Nervous system consequences of COVID-19 – Science

Related:

Perspective | Post-acute neurological consequences of COVID-19: an unequal burden – “COVID-19 and its neurological consequences particularly burden marginalized communities, and so can only be effectively treated by advancing health equity”.

Review: Counting the neurological cost of COVID-19.

Infection with Covid-19 carries a much higher risk of developing neurological complications than Covid-19 vaccines.

M-A: Frequency of Neurologic Manifestations in COVID-19 – up to one-third of patients (89% hospitalized) experienced at least one neurological manifestation.

Neurological Effects of COVID-19 in Children.

Cohort study: Neurological manifestations of SARS-CoV-2 infection in hospitalized children and adolescents in the UK – “around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection”.

International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.

Short review: Neurological complications of COVID-19.

2 new meta-analysis detail neurologic and psychiatric conditions in COVID-19.

M-A: Encephalitis as Neurological Complication of COVID‐19.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditionsEight out of ten people hospitalized with COVID-19 develop neurological problems – the most common self-reported symptoms included headache (37%) and anosmia or ageusia (26%).

[Preprint] Frequency of neurological manifestations in COVID-19: a systematic review and meta-analysis of 350 studies – up to one-third of COVID-19 patients analyzed in this review, 89% of whom were hospitalized, experienced at least one neurological manifestation

 

Commentary on Twitter

 


Systematic Review: In people with Alzheimer’s disease and vascular dementia with agitation and psychosis, atypical antipsychotics probably reduce agitation slightly (moderate‐certainty evidence) but probably have a negligible effect on psychosis or risk of any adverse event.

21 Jan, 2022 | 09:50h | UTC

Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia – Cochrane Library

Summary: Do antipsychotic medicines reduce  agitated behaviour and psychotic symptoms in people with Alzheimer’s disease and vascular dementia? – Cochrane Library

 


An updated overview of low back pain management.

21 Jan, 2022 | 09:23h | UTC

An Updated Overview of Low Back Pain Management – Asian Spine Journal

 


Review: Cannabis-based medicines and medical cannabis for chronic neuropathic pain.

20 Jan, 2022 | 08:39h | UTC

Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain – CNS Drugs

Related:

Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions.

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain.

The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use.

Cannabis products are being sold as sleep remedies – here’s the evidence about their effectiveness.

Guideline: Medical cannabis or cannabinoids for chronic pain.

Cannabis and Cannabinoid Analgesia position statement – “Due to the lack of high-quality clinical evidence, the IASP does not currently endorse general use of cannabis and cannabinoids for pain relief.”

NICE Guideline: Cannabis-Based Medicinal Products

Consensus recommendations for perioperative management of cannabis and cannabinoid-based medicine users

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain – Agency for Healthcare Research and Quality

Short Review: Drug Interactions with Cannabinoids

Meta-Analysis: Cannabinoids Not Effective for Cancer-Related Pain

 


RCT: Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia.

19 Jan, 2022 | 08:11h | UTC

Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study – The Lancet Neurology (link to abstract – $ for full-text)

Commentary: Mixed Salts Oxybate Improves Daytime Performance in Individuals with Idiopathic Hypersomnia – Practical Neurology

 


Perspective | Post-acute neurological consequences of COVID-19: an unequal burden – “COVID-19 and its neurological consequences particularly burden marginalized communities, and so can only be effectively treated by advancing health equity”.

18 Jan, 2022 | 09:44h | UTC

Post-acute neurological consequences of COVID-19: an unequal burden – Nature Medicine

 


Multicenter observational study: Reconstruction of paralyzed arm function in patients with hemiplegia through contralateral seventh cervical nerve cross transfer.

18 Jan, 2022 | 09:13h | UTC

Reconstruction of paralyzed arm function in patients with hemiplegia through contralateral seventh cervical nerve cross transfer: a multicenter study and real-world practice guidance – EClinicalMedicine

 


AAN Position Statement: Consent Issues in the Management of Acute Ischemic Stroke.

14 Jan, 2022 | 08:24h | UTC

Consent Issues in the Management of Acute Ischemic Stroke: AAN Position Statement – Neurology

News Release: Who gives consent for treatment when a person with stroke cannot? – American Academy of Neurology

 


Study provides evidence of causality between Epstein-Barr virus and multiple sclerosis.

14 Jan, 2022 | 08:23h | UTC

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis – Science (link to abstract – $ for full-text)

Commentaries:

Strong new evidence suggests a virus triggers multiple sclerosis – STAT

Study identifies Epstein-Barr as a leading candidate for cause of Multiple Sclerosis – Uniformed Services University of the Health Sciences (USU)

Epstein-Barr virus may be leading cause of multiple sclerosis – Harvard T.H. Chan School of Public Health

 


Review: Migraine.

14 Jan, 2022 | 08:16h | UTC

Migraine – Nature Reviews Disease Primers (if the link is paywalled, try this one)

Infographic: Migraine (if the link is paywalled, try this one)

 


RCT: In patients with Parkinson disease uncontrolled with Levodopa, MAO-B inhibitors or dopamine agonists as adjuvant therapies were associated with better patient-rated quality of life compared to COMT inhibitors.

14 Jan, 2022 | 08:15h | UTC

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial – JAMA Neurology

 

Commentary on Twitter

 


Recommendations for traveling to altitude with neurological disorders.

14 Jan, 2022 | 08:11h | UTC

Recommendations for traveling to altitude with neurological disorders – Journal of Central Nervous System Disease

 


Systematic Review: Ketamine for the treatment of mental health and substance use disorders.

14 Jan, 2022 | 08:08h | UTC

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review – BJPsych Open

Commentaries:

Ketamine therapy swiftly reduces depression and suicidal thoughts – University of Exeter

Ketamine May Quickly Ease Tough-to-Treat Depression – HealthDay

 


RCT: In full-term and near-term neonates, drug treatment of all clinically and electrographically detected seizures was not associated with reduced death rates or disability at 2 years compared with the treatment of only the clinically detected seizures.

13 Jan, 2022 | 08:24h | UTC

Effect of Treatment of Clinical Seizures vs Electrographic Seizures in Full-Term and Near-Term Neonates: A Randomized Clinical Trial – JAMA Network Open

Commentaries:

Should we treat electrographic seizures? – Neonatal Research

Subclinical Electrographic Seizures in the Newborn—Is More Treatment Better? – JAMA Network Open

Neonatal Seizures: Little Difference Between EEG/Clinical Treatment – Physician’s Weekly

 

Commentary on Twitter

 


Podcast: Long COVID Pearls.

12 Jan, 2022 | 09:04h | UTC

#315 Long COVID with Dr. Monica Verduzco-Gutierrez – The Curbsiders

 


Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.

11 Jan, 2022 | 02:38h | UTC

Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 – The Lancet Public Health

News Release: Global dementia cases set to triple by 2050 unless countries address risk factors – The Lancet

Commentaries:

Forecasting the prevalence of dementia – The Lancet Public Health

Dementia cases expected to almost triple across the world by 2050 – BBC

Number of adults with dementia to exceed 150m by 2050, study finds – The Guardian

 

Commentary on Twitter (thread – click for more)

 


Special Issue: Peri‐operative and critical care management of the brain ‐ current evidence.

11 Jan, 2022 | 02:36h | UTC

Homepage: Special Issue:Peri‐operative and critical care management of the brain ‐ current evidence – Anaesthesia

Editorials:

In search of the perfect outcome in neuroanaesthesia and neurocritical care

Anaesthesia and the older brain: what should we do?

Review Articles:

Implications of nocebo in anaesthesia care

Chronic subdural haematoma: the role of peri-operative medicine in a common form of reversible brain injury

Acute peri-operative neurocognitive disorders: a narrative review

Pragmatic sedation strategies to prevent secondary brain injury in low-resource settings

Delirium and COVID-19: a narrative review of emerging evidence

Anaesthesia for mechanical thrombectomy: a narrative review

Clinical applications of point-of-care ultrasound in brain injury: a narrative review

Management of status epilepticus: a narrative review

Evidence-based strategies to reduce the incidence of postoperative delirium: a narrative review

Management of traumatic brain injury: a narrative review of current evidence

Peri-operative neurological monitoring with electroencephalography and cerebral oximetry: a narrative review

Peri-operative management of patients with Parkinson’s disease

 


M-A: Fatigue and cognitive impairment in Post-COVID-19 Syndrome.

11 Jan, 2022 | 01:28h | UTC

Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis – Brain, Behavior, and Immunity

 


AAN Guideline: Oral and topical treatment of painful diabetic polyneuropathy.

8 Jan, 2022 | 23:18h | UTC

Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee – Neurology

News Release: AAN Issues Guideline for Treatment of Painful Diabetic Neuropathy – American Academy of Neurology

 


Autoimmune encephalitis after SARS-CoV-2 infection: case frequency, findings, and outcomes.

16 Dec, 2021 | 09:47h | UTC

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes – Neurology

 

Commentary on Twitter

 


Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions.

14 Dec, 2021 | 08:44h | UTC

News release: Cannabis use could cause harmful drug interactions – Washington State University

Original Study: Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions – Drug Metabolism and Disposition

 


Review: Neuropsychiatric assessment and management of the ICU survivor.

10 Dec, 2021 | 10:01h | UTC

Neuropsychiatric assessment and management of the ICU survivor – Cleveland Clinic Journal of Medicine

 


AAN Practice Advisory: Antiseizure medication withdrawal in patients who are seizure-free.

8 Dec, 2021 | 09:59h | UTC

Antiseizure Medication Withdrawal in Seizure-Free Patients: Practice Advisory Update Summary: Report of the AAN Guideline Subcommittee – Neurology

 


Systematic Review: What are the benefits and risks of electrical spinal cord and dorsal root ganglion stimulation for the treatment of chronic pain in adults?

7 Dec, 2021 | 08:31h | UTC

Summary: What are the benefits and risks of electrical spinal cord and dorsal root ganglion stimulation for the treatment of chronic pain in adults? – Cochrane Library

Original study: Implanted spinal neuromodulation interventions for chronic pain in adults – Cochrane Library

 


Association of resting heart rate with cognitive decline and dementia in older adults: A population-based cohort study.

5 Dec, 2021 | 23:17h | UTC

Association of resting heart rate with cognitive decline and dementia in older adults: A population-based cohort study – Alzheimer’s & Dementia

News Release: Elevated heart rate linked to increased risk of dementia – Karolinska Intitutet

 


Stay Updated in Your Specialty

No spam, just news.